Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Treatment with dapsone, topical corticosteroids, and antibiotics improved the man's skin conditions.

This study evaluated the molecular mechanisms, clinical efficacy, and safety of off-label therapies for male androgenetic alopecia and determined the relative efficacy of these therapies compared to topical minoxidil through a network meta-analysis.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

In this Stanford study, verteporfin was used to promote scarless skin regeneration by inhibiting YAP activity in a 27-year-old female, resulting in increased hair density at the treated site compared to the untreated control.

Some sunscreen ingredients may be linked to hair loss, but more research is needed.

This study found that in a mouse model of Focal Dermal Hypoplasia, treatment with lithium carbonate improved skin disease symptoms compared to controls, though disease severity varied and posed interpretation challenges.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This study reported that topical drugs regrew hair in mice.

This review discusses methotrexate's use in dermatology and its mechanisms, pharmacokinetics, dosing, side effects, interactions, and emphasizes the need for further research into optimizing therapy and predicting adverse events.

This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.

This review discusses the applications of the 308-nm excimer laser in treating various dermatologic conditions and suggests treatment is generally well tolerated, but calls for larger long-term studies.

This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.

This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.

Gepant medications for migraines show varied safety profiles in this study, with specific adverse events reported across systems like gastrointestinal and skin disorders, highlighting the need for tailored treatment and monitoring.

In this retrospective study, oral isotretinoin monotherapy effectively achieved remission in 82% of patients with folliculitis decalvans, with those receiving ≥0.4 mg/kg/day for ≥3 months experiencing better outcomes and less frequent relapse.

This article reviews current research on animal models for hair regrowth treatments and reports no new findings; it highlights the need for studies comparing therapy efficiency and long-term safety.

This abstract discusses advancements in hair transplantation technology, highlighting the role of robotics and follicular unit extraction/grafting in achieving excellent clinical outcomes, with adjuvant treatments like platelet-rich plasma, lasers, and stem cells potentially improving the durability and appearance of results.

Lasers in hair transplantation show promise but are not yet standard, with current methods causing some side effects and needles still being preferred for creating recipient sites.

This case report describes the first known instance of fixed drug eruption linked to finasteride, confirmed through an oral challenge test that reproduced symptoms at the same skin site.

This review summarizes existing literature on the safety of commonly used dermatologic medications during pregnancy but does not present new clinical findings, aiming to assist physicians with prescribing decisions.

This study reviews current methods and emerging approaches to prevent and treat chemotherapy-induced hair loss, reporting that evidence-based research is needed to validate effective strategies, which could enhance cancer patients’ quality of life and treatment compliance.

In this real-world study, low-level laser helmet therapy for androgenetic alopecia showed that male patients with specific scalp conditions may have better results after more than 180 uses or a year of treatment.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

This review discusses the clinical challenges in treating alopecia areata with off-label therapies, highlighting the need to consider new research on JAK inhibitors, but reports no new clinical results.

This case report describes significant symptom improvement and hair regrowth in a man with recalcitrant folliculitis decalvans after starting tirzepatide for weight management, suggesting a potential new therapy avenue.

A new method improves the isolation of hair follicle cells for better hair growth research.

This study found that new methods for isolating human dermal papilla cells were more efficient than traditional methods, maintaining higher levels of specific markers and improving the cells' research potential.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

In this study, researchers developed a new microneedle patch delivery system for minoxidil, which enhanced its controlled release and improved hair growth in mice, potentially offering better treatment outcomes for androgenetic alopecia.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.